Autopsy report · NCT03566485

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

“Low accrual/Loss of funding”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 5 months before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Vanderbilt-Ingram Cancer Center

Sponsor type

University, hospital or other

Conditions

Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Estrogen Receptor-positive

Interventions

Atezolizumab; Cobimetinib; Idasanutlin

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
  “Low Accrual, Funding” (90% match in meaning)
• Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy
  “funding issues and poor accrual” (85% match in meaning)
• Gated and Non-Gated Dynamic PET/CT Imaging
  “Loss of funding” (83% match in meaning)
• Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation
  “Funding loss” (80% match in meaning)
• Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
  “Lack of funding and slow accrual” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.